Grant: Master's Award: Canada Graduate Scholarships
University of Toronto
$17,500.00
Discovery and translation of novel immune checkpoints for cancer immunotherapy through the CellectSeq approach
FY 2016-17
Summary
The immune system has evolved to constantly survey and eliminate cancer cells developing within the body. It achieves this through flagging them for destruction by specialized immune cells termed T cells. Increasingly, it is recognized that cancer cells are highly adaptive and find ways to escape killing by T cells, a process known as immune evasion. A major cause of immune evasion is by driving T cells to become inhibited or exhausted through molecules known as immune checkpoints. As such, cancer cells use these molecules to switch off T cells, preventing their ability to destroy cancer cells. Interestingly, recent breakthroughs have targeted immune checkpoints using drugs known as antibodies. Antibodies bind to immune checkpoints and block the inhibition of T cell function. They are currently used to treat and cure several types of cancers. While promising, current treatments are only successful in a subset of patients and cancer-types. As a result, the field has focused on identifying new immune checkpoints that could be co-targeted to improve existing therapies. Here we propose to use a novel approach, termed CellectSeq, to identify novel immune checkpoints. It achieves this by searching for molecules that are uniquely present on exhausted T cells but absent on cancer killing T cells. Once identified, antibodies targeting these molecules will be developed to determine their ability to reverse T cell exhaustion. These antibodies could then be used to enhance immune-mediated killing of cancer cells in hopes of improving treatments for cancer by improving long-term cure rates. Through the extensive expertise network, abundant resources and collaborative environment within the Moffat Lab, I am confident that this project will be successful.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
367368
Name
Tieu David
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Discovery and translation of novel immune checkpoints for cancer immunotherapy through the CellectSeq approach
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Activated T Cells; Biomarkers; Cancer; Cellectseq; Exhausted T Cells; Immune Checkpoints; Immunotherapeutics; Immunotherapy; Naive T Cells; Protein Epitopes
Abstract
The immune system has evolved to constantly survey and eliminate cancer cells developing within the body. It achieves this through flagging them for destruction by specialized immune cells termed T cells. Increasingly, it is recognized that cancer cells are highly adaptive and find ways to escape killing by T cells, a process known as immune evasion. A major cause of immune evasion is by driving T cells to become inhibited or exhausted through molecules known as immune checkpoints. As such, cancer cells use these molecules to switch off T cells, preventing their ability to destroy cancer cells. Interestingly, recent breakthroughs have targeted immune checkpoints using drugs known as antibodies. Antibodies bind to immune checkpoints and block the inhibition of T cell function. They are currently used to treat and cure several types of cancers. While promising, current treatments are only successful in a subset of patients and cancer-types. As a result, the field has focused on identifying new immune checkpoints that could be co-targeted to improve existing therapies. Here we propose to use a novel approach, termed CellectSeq, to identify novel immune checkpoints. It achieves this by searching for molecules that are uniquely present on exhausted T cells but absent on cancer killing T cells. Once identified, antibodies targeting these molecules will be developed to determine their ability to reverse T cell exhaustion. These antibodies could then be used to enhance immune-mediated killing of cancer cells in hopes of improving treatments for cancer by improving long-term cure rates. Through the extensive expertise network, abundant resources and collaborative environment within the Moffat Lab, I am confident that this project will be successful.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Tieu, David
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~